Video

ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

Author(s):

Sam Klempner, MD, Massachusetts General Hospital Daniel H. Ahn, DO, Mayo Clinic

Key opinion leaders in gastric cancers comment on ESMO 2021 updates in metastatic HER2+ esophagogastric adenocarcinoma and metastatic HER2+ gastric or gastroesophageal junction cancer.

Data from the following clinical trials are discussed:

  • LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2-positive locally advanced or metastatic esophagogastric adenocarcinoma (EGA): Results of the randomized phase 2 INTEGA trial (INTEGA)
  • LBA55 - Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric02)
Related Videos
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Haeseong Park, MD, MPH
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Related Content
Haibo Qiu, MD
June 4th 2024

Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Arndt Vogel, MD
June 2nd 2024

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Jens Hoeppner, FAChirg, FACS, MD
June 2nd 2024

Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer

FDA
May 31st 2024

FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma